Inefficiencies in Technology Transfer: Theory and Empirics
暂无分享,去创建一个
[1] James Kalamas,et al. The optimum time for drug licensing , 2003, Nature Reviews Drug Discovery.
[2] Howard W. Smith,et al. Department of Economics Discussion Paper Series Upstream Competition and Downstream Buyer Power Upstream Competition and Downstream Buyer Power , 2022 .
[3] S. Vishwasrao,et al. Royalties vs. fees: How do firms pay for foreign technology? , 2007 .
[4] Massimo Motta,et al. Competition Policy: Theory and Practice , 2004 .
[5] Todd A. Surovell,et al. The Tortoise and the Hare , 2000, Current Anthropology.
[6] M. Shubik,et al. Market structure and behavior , 1982 .
[7] A. Rubinstein,et al. The Nash bargaining solution in economic modelling , 1985 .
[8] Ashish Arora,et al. Does In-House R&D Increase Bargaining Power? Evidence from the Pharmaceutical Industry , 2004 .
[9] A. Arora,et al. Markets for Technology: The Economics of Innovation and Corporate Strategy , 2002 .
[10] Gary P. Pisano,et al. R&D Performance, Collaborative Arrangements and the Market for Know-How: A Test of the "Lemons" Hypothesis in Biotechnology , 1997 .
[11] Josh Lerner,et al. Contractibility and the Design of Research Agreements , 2004 .
[12] Lars Stole,et al. Intra-firm Bargaining under Non-binding Contracts , 1996 .
[13] R. Merges,et al. The Control of Technology Alliances: An Empirical Analysis of the Biotechnology Industry , 2003 .
[14] Graham Watt,et al. The tortoise and the hare. , 2011, The British journal of general practice : the journal of the Royal College of General Practitioners.
[15] A. Raskovich,et al. Ordered Bargaining , 2007 .
[16] M. Drugov. Information and Delay in an Agency Model , 2010 .
[17] Matthew J. Higgins. The Allocation of Control Rights in Pharmaceutical Alliances , 2006 .
[18] Jay Pil Choi,et al. Technology Transfer with Moral Hazard , 1996 .
[19] Anna Levine,et al. Licensing and Scale Economies in the Biotechnology Pharmaceutical Industry , 2009 .
[20] S. Hart,et al. HANDBOOK OF GAME THEORY , 2011 .
[21] D. Fudenberg,et al. Infinite-Horizon Models of Bargaining with One-Sided Incomplete Information , 1985 .
[22] J. Gans,et al. Vertical Integration in the Presence of Upstream Competition , 2004 .
[23] Pedro Mendi,et al. The Structure of Payments in Technology Transfer Contracts: Evidence from Spain , 2005 .
[24] Lawrence M. Ausubel,et al. Bargaining in Incomplete Information , 2002 .
[25] Leslie M. Marx,et al. Opportunism in Multilateral Vertical Contracting: Nondiscrimination, Exclusivity, and Uniformity: Comment , 2004 .
[26] T. Cymet,et al. The Truth about Drug Companies: How They Deceive Us and What to Do about It , 2006 .
[27] Nicos Savva,et al. The economics of licensing contracts. , 2008, Nature biotechnology.
[28] Sean Nicholson,et al. Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality , 2002 .
[29] T. Khanna,et al. The Structure of Licensing Contracts , 2003 .
[30] Y. Tauman,et al. Fees Versus Royalties and the Private Value of a Patent , 1986 .
[31] A. Raskovich. Competition or Collusion? Negotiating Discounts Off Posted Prices , 2013 .
[32] James J. Anton,et al. The Sale of Ideas: Strategic Disclosure, Property Rights, and Contracting , 2002 .
[33] Randall Wright,et al. Search and the market for ideas , 2010, J. Econ. Theory.
[34] Leslie M. Marx,et al. Opportunism in Multilateral Vertical Contracting : Nondiscrimination , Exclusivity , and Uniformity : Reply , 2004 .
[35] A. Beggs. The licensing of patents under asymmetric information , 1992 .